title: Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine and during exercise.
abstract: Although transdermal nicotine patches have been studied extensively under recommended conditions, the present studies were designed to assess the nicotine plasma levels and the safety of transdermal nicotine patches in smokers undergoing situations suspected to result in increased nicotine plasma levels. The first study examined the effects of increasing nicotine intake through sequential administration of a nicotine patch (day 2), a patch followed by consumption of nicotine gum (day 3), and a patch followed by gum consumption and cigarette smoking (day 4). In this study, nicotine plasma levels increased transiently after the addition of each nicotine source. Mean areas under the concentration-time curves from 0 to 24 hours (AUC0-24) for nicotine were 453 +/- 120 ng.hr/mL (day 2), 489 +/- 143 ng.hr/mL (day 3), and 485 +/- 143 ng.hr/mL (day 4). The second study evaluated the effects of physical exercise on the kinetics and the safety of two different types of nicotine transdermal devices: Nicoderm and Habitrol. The mean delivered dose of nicotine was higher with Nicoderm compared with Habitrol, and the two products were not considered to be bioequivalent. During a 20-minute exercise period, nicotine plasma levels increased by 13 +/- 9% for Nicoderm and 30 +/- 20% for Habitrol. This increase in nicotine plasma levels was probably related to the exercise-induced increase in peripheral circulation at the patch site. Results from both studies indicate a clinically nonsignificant increase in blood pressure and heart rate after the administration of nicotine. After exercise, subjects taking Habitrol tended to have a higher incidence of adverse events compared with baseline values. Safety profiles remained acceptable in both studies despite the increases in nicotine plasma levels. It was concluded that both superimposed nicotine sources and physical exertion result in short-lived plasma nicotine elevations and temporarily increase nicotine pharmacodynamic parameters without increased risk to the volunteers.
authors.affiliation: Hoechst Marion Roussel Canada, Inc., Laval, Canada.
authors.forename: W
authors.initials: W
authors.lastname: Homsy
authors.forename: K
authors.initials: K
authors.lastname: Yan
authors.forename: J M
authors.initials: JM
authors.lastname: Houle
authors.forename: J G
authors.initials: JG
authors.lastname: Besner
authors.forename: D
authors.initials: D
authors.lastname: Gossard
authors.forename: C H
authors.initials: CH
authors.lastname: Pierce
authors.forename: G
authors.initials: G
authors.lastname: Caillé
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D002638:Chewing Gum; D004311:Double-Blind Method; D015444:Exercise / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D018722:Nicotinic Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D012907:Smoking / Q000378:metabolism
chemical_list: D002638:Chewing Gum; D018722:Nicotinic Agonists; D009538:Nicotine